Target intelligence / Profile preview

Peptidoglycan pentaglycyl bridging segment

Molecular classification
Bacterial cell wall component, Peptidoglycan structural element, Other
01

Overview

The peptidoglycan pentaglycyl bridging segment is a vital structural element of the cell wall in certain Gram-positive bacteria, most notably Staphylococcus aureus (Schleifer & Kandler, 1972). It consists of five glycine residues that form a cross-link between the L-lysine of one muropeptide stem and the D-alanine of an adjacent stem, providing the cell wall with the tensile strength required to resist high internal osmotic pressure (Thumm & Götz, 1997). This specific bridge is the primary target for the antimicrobial enzyme lysostaphin, which acts as a zinc-dependent glycylglycine endopeptidase to cleave the glycine-glycine bonds (Bastos et al., 2010). Because this pentaglycine structure is highly characteristic of staphylococci, it allows for targeted lysis of these pathogens while sparing other bacterial species. Resistance can occur through the incorporation of serine residues into the bridge, mediated by the lif or epr genes, which reduces the binding and cleavage efficiency of bridge-targeting agents (DeHart et al., 1995). Understanding this target is crucial for developing 'enzybiotics' and other narrow-spectrum treatments for multidrug-resistant infections like MRSA.

Other names
Pentaglycine bridgePentaglycyl cross-linkGly5 bridgeInterpeptide bridgePentaglycine interpeptide bridge
02

Mechanism of action

Endopeptidase-mediated cleavage of the glycyl-glycine bonds within the pentaglycine bridge, leading to cell wall degradation and osmotic lysis.

03

Biological functions

Cell wall stabilizationPeptidoglycan cross-linkingMaintenance of osmotic integrityOther
04

Disease associations

Infection
05

Safety considerations

Development of resistance via bridge modification (e.g., Gly-to-Ser substitution)Immunogenicity of therapeutic enzymes (e.g., lysostaphin)Narrow spectrum of activity limited to specific staphylococcal species
06

Interacting drugs

Lysostaphin
07

Biomarkers

Bacterial cell wall fragmentsPeptidoglycan-derived muropeptides

Beyond the preview

Go deeper on Peptidoglycan pentaglycyl bridging segment.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptidoglycan pentaglycyl bridging segment.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call